5 Dealmaking Trends To Watch In 2022
Executive Summary
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
You may also be interested in...
AbbVie Exits CAR-T Cell Therapy Development Partnership With Caribou
Deal Snapshot: The companies had announced the deal back in February 2021, but citing its “strategic focus,” AbbVie told Caribou it was backing out.
Make, Buy Or Partner: Strategic Alliances Continue To Fuel Biopharma Growth
The biopharma market has been highly active throughout the COVID-19 pandemic with a substantial focus on strategic alliances between 2020-H1 2021. Partnership deals present exciting liquidity and risk mitigation opportunities for early-stage companies. Small molecules still comprise the largest segment of partnered drugs, but alliances for other modalities are on the rise.
Improving Clinical Trials In Psychiatric Health Care
Kiri Granger, Monument Therapeutics’ chief scientific officer and executive director, and one of In Vivo’s 2022 Rising Leaders, hopes to take the company to the next level by rejecting the conventional one-size-fits-all approach to psychiatric clinical trials.